Tags

Type your tag names separated by a space and hit enter

Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study.
Am J Gastroenterol. 1996 Feb; 91(2):223-7.AJ

Abstract

OBJECTIVE

To compare ranitidine to misoprostol with respect to the prevention of gastric and duodenal ulcers in patients on chronic NSAID therapy.

METHODS

A multi-center, 8-wk, randomized, double-blind study. Eligible patients were on chronic NSAID therapy and were experiencing NSAID-related upper gastrointestinal (UGI) pain without UGI endoscopic evidence of gastric or duodenal ulcers. Patients enrolled in the study were randomized to either misoprostol 200 micrograms q.i.d. or ranitidine 150 mg b.i.d.. Follow-up UGI endoscopy was performed after 4 and 8 wk of treatment. Therapeutic failure was considered the development of a gastric or duodenal ulcer > or = 0.3 cm in diameter with perceptible depth.

RESULTS

Gastric ulcers were found in only 1/180 (0.56%) patient on misoprostol and in 11/194 (5.67%) patients on ranitidine, a difference that was statistically significant (p < 0.01). Duodenal ulcer rates were similar for the ranitidine (2/185 or 1.08%) and misoprostol (2/181 or 1.10%) groups.

CONCLUSION

Misoprostol is significantly more effective than ranitidine in the prevention of NSAID-induced gastric ulcers. Ranitidine was as effective as misoprostol for the prevention of NSAID-induced duodenal ulcers. Misoprostol should be used for prophylaxis against both gastric and duodenal ulceration in patients on chronic NSAID therapy.

Authors+Show Affiliations

Department of Veterans Affairs Medical Center, Miami, Florida, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8607484

Citation

Raskin, J B., et al. "Misoprostol and Ranitidine in the Prevention of NSAID-induced Ulcers: a Prospective, Double-blind, Multicenter Study." The American Journal of Gastroenterology, vol. 91, no. 2, 1996, pp. 223-7.
Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol. 1996;91(2):223-7.
Raskin, J. B., White, R. H., Jaszewski, R., Korsten, M. A., Schubert, T. T., & Fort, J. G. (1996). Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. The American Journal of Gastroenterology, 91(2), 223-7.
Raskin JB, et al. Misoprostol and Ranitidine in the Prevention of NSAID-induced Ulcers: a Prospective, Double-blind, Multicenter Study. Am J Gastroenterol. 1996;91(2):223-7. PubMed PMID: 8607484.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. AU - Raskin,J B, AU - White,R H, AU - Jaszewski,R, AU - Korsten,M A, AU - Schubert,T T, AU - Fort,J G, PY - 1996/2/1/pubmed PY - 1996/2/1/medline PY - 1996/2/1/entrez SP - 223 EP - 7 JF - The American journal of gastroenterology JO - Am J Gastroenterol VL - 91 IS - 2 N2 - OBJECTIVE: To compare ranitidine to misoprostol with respect to the prevention of gastric and duodenal ulcers in patients on chronic NSAID therapy. METHODS: A multi-center, 8-wk, randomized, double-blind study. Eligible patients were on chronic NSAID therapy and were experiencing NSAID-related upper gastrointestinal (UGI) pain without UGI endoscopic evidence of gastric or duodenal ulcers. Patients enrolled in the study were randomized to either misoprostol 200 micrograms q.i.d. or ranitidine 150 mg b.i.d.. Follow-up UGI endoscopy was performed after 4 and 8 wk of treatment. Therapeutic failure was considered the development of a gastric or duodenal ulcer > or = 0.3 cm in diameter with perceptible depth. RESULTS: Gastric ulcers were found in only 1/180 (0.56%) patient on misoprostol and in 11/194 (5.67%) patients on ranitidine, a difference that was statistically significant (p < 0.01). Duodenal ulcer rates were similar for the ranitidine (2/185 or 1.08%) and misoprostol (2/181 or 1.10%) groups. CONCLUSION: Misoprostol is significantly more effective than ranitidine in the prevention of NSAID-induced gastric ulcers. Ranitidine was as effective as misoprostol for the prevention of NSAID-induced duodenal ulcers. Misoprostol should be used for prophylaxis against both gastric and duodenal ulceration in patients on chronic NSAID therapy. SN - 0002-9270 UR - https://www.unboundmedicine.com/medline/citation/8607484/Misoprostol_and_ranitidine_in_the_prevention_of_NSAID_induced_ulcers:_a_prospective_double_blind_multicenter_study_ DB - PRIME DP - Unbound Medicine ER -